| Dr Paul Morphy, PHD CCC-SLP | |
|
6325 91st St Ne, Marysville, WA 98270-2898 | |
| (360) 965-1966 | |
| Not Available |
| Full Name | Dr Paul Morphy |
|---|---|
| Gender | Male |
| Speciality | Speech-language Pathologist |
| Location | 6325 91st St Ne, Marysville, Washington |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114551611 | NPI | - | NPPES |
| 30007774 | Medicaid | NH |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | LL60870882 (Washington) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paul Morphy, PHD CCC-SLP 6325 91st St Ne, Marysville, WA 98270-2898 Ph: (360) 965-1966 | Dr Paul Morphy, PHD CCC-SLP 6325 91st St Ne, Marysville, WA 98270-2898 Ph: (360) 965-1966 |
News Archive
In the largest study of skin cancer rates among gay, lesbian or bisexual individuals, investigators from Brigham and Women's Hospital report important differences in skin cancer prevalence among sexual minorities. Rates of skin cancer were higher among gay and bisexual men compared to heterosexual men but lower among bisexual women than heterosexual women.
Patients who combine the common over-the counter pain medications ibuprofen and naproxen with aspirin have a risk of gastrointestinal complications including ulcers, perforations and bleeding that is two to three times greater than patients who take these medications but do not combine them with aspirin.
The U.S. Food and Drug Administration today approved Beleodaq (belinostat) for the treatment of patients with peripheral T-cell lymphoma (PTCL), a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency's accelerated approval program.
ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today provided an update on its Phase III program with pimavanserin for Parkinson's disease psychosis (PDP), which is being pursued in collaboration with Biovail Laboratories International SRL ("Biovail"), a subsidiary of Biovail Corporation.
› Verified 1 days ago
Deborah Bradley, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th St Ne, Marysville, WA 98270 Phone: 360-653-0896 | |
Graham Lucas Chattin, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th St Ne, Marysville, WA 98270 Phone: 360-965-0000 | |
Miss Barbara Andrea Herrera Rojas, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 14500 51st Ave Ne, Marysville, WA 98271 Phone: 360-965-8687 | |
Marysville School District Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th Street Ne, Marysville School District, Marysville, WA 98270 Phone: 360-653-7058 Fax: 360-657-6824 | |
Maryann Walters, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4220 80th St Ne, Marysville, WA 98270 Phone: 360-653-7058 | |
Caitlin Schauer, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 4407 116th St Ne, Marysville, WA 98271 Phone: 360-965-1649 |